As big pharma ADC collaborations spiked the total life sciences partnership activity in 2023, including $4.6 billion in total upfront cash and equity for ADC licensing deals as an all-time high, industry’s appetite for ADCs as a cornerstone of corporate strategy to drive business growth is driving more companies to seek creative partnerships, to drive capital through pharma deals.   

The complexities of ADC intellectual property, M&A and transactions requires credible and experienced advisors, with unique and proven record in this specialised area of life sciences.  

Business development leaders looking to initiate transactions whilst the market favours their success are seeking opportunistic capital for the flexible runway, advice on deal structure and protecting IP, and investment banks engaging with investors to raise their visibility.  

Align your expertise with the interests of our targeted, hyper-relevant audience from both sides of buy and sell, needing to do deals across ADCs.  

Get in touch at sponsor@hansonwade.com or download the event guide for more information